ZDHHC17 Links S-Acylation, Huntington Disease, VCP-associated Multisystem Proteinopathy, and Amyotrophic Lateral Sclerosis.

This study identifies ZDHHC17 as a critical S-acyltransferase that regulates the localization and toxicity of key proteins (including VCP and TDP-43) across multiple neurodegenerative diseases, revealing a shared mechanism of protein mislocalization driven by disrupted S-acylation.

The Gist

The Big Picture: The "Sticky" Problem in the Brain

Imagine your brain is a bustling city. Every cell in the city has a specific job, and every protein inside those cells is like a delivery truck or a worker that needs to be in the right place at the right time to keep the city running.

Sometimes, in diseases like Huntington's, ALS (Lou Gehrig's disease), and VCP-associated proteinopathy, these "workers" get lost. They end up in the wrong neighborhoods (like the wrong part of the cell), causing traffic jams, accidents, and eventually, the city starts to crumble. This is called protein mislocalization.

This paper asks: Why do these workers get lost?

The answer lies in a tiny, invisible "sticky note" called S-acylation (or palmitoylation). Think of S-acylation as a greasy, oily sticker that the cell attaches to proteins. This sticker acts like a GPS tag or a magnet, telling the protein: "Stick to the membrane here!" or "Go to the nucleus there!" Without this sticker, the protein floats aimlessly and gets lost.

The Main Character: ZDHHC17 (The Master Gluer)

The researchers discovered a specific enzyme (a biological machine) called ZDHHC17. You can think of ZDHHC17 as the Master Gluer of the cell. Its job is to apply those "sticky oily stickers" to proteins to make sure they stay in the right place.

The paper shows that when ZDHHC17 isn't working right, or when it gets confused, it causes major problems in three different neurodegenerative diseases. It turns out that ZDHHC17 is a "shared villain" (or a shared key) across these different conditions.

The Key Findings: What Happened in the Lab?

The team looked at several famous "bad actors" in brain diseases: VCP, TDP-43, FUS, and SQSTM1 (p62). These are proteins that, when they get lost, cause brain cells to die.

Here is what they found, broken down simply:

1. The "Sticky" Status is Broken in Disease
In mice models of Huntington's disease, the researchers found that these proteins were losing their "sticky stickers" (S-acylation).

• Analogy: Imagine a delivery truck (the protein) that usually has a magnetic strip (the sticker) to stick to the road. In Huntington's disease, the magnet is turned off. The truck falls off the road and crashes.
• Specifically, the protein SQSTM1 lost about 50% of its stickiness in older mice, which matched what they saw in human patients.

2. ZDHHC17 is the Glue for VCP and TDP-43
The team tested if ZDHHC17 was the one applying the stickers.

• For TDP-43: ZDHHC17 interacts with it, but strangely, it doesn't seem to use the "sticky" method to move it. It just grabs it and pulls it out of the nucleus (the cell's control center).
• For VCP: ZDHHC17 does put the sticky sticker on VCP. But here's the twist: when ZDHHC17 puts too much sticker on a mutant version of VCP (the broken version found in patients), it actually makes the cell sicker. It causes the cell to stress out and die (a process called paraptosis).
• Analogy: It's like a mechanic (ZDHHC17) trying to fix a broken car (mutant VCP). The mechanic puts a new tire on it, but because the car's frame is bent, the new tire makes the car wobble even more, causing it to crash.

3. The Fly Test: What happens if we remove the Gluer?
To prove this was important, they used fruit flies (Drosophila). The fly version of ZDHHC17 is called dHip14.

• The "All-Over" Removal: When they removed dHip14 from the entire fly body, the flies couldn't even hatch from their pupal cases. They died before they could become adults.
• The "Motor Neuron" Removal: When they removed dHip14 only from the motor neurons (the nerves that control movement), the flies could still hatch, but they couldn't climb. They became weak and clumsy, just like humans with ALS.
• Analogy: If you remove the Master Gluer from the whole city, the city shuts down completely (lethality). If you only remove it from the police force (motor neurons), the city is still standing, but the police can't get to the crime scenes, and chaos ensues (motor deficits).

4. The Human Connection
They looked at cells from real patients with VCP mutations. They found that the broken VCP protein in these patients had more sticky stickers than normal. This suggests that the "Master Gluer" is over-enthusiastically gluing the broken protein, which makes the situation worse.

Why Does This Matter?

This paper connects the dots between three very different diseases (Huntington's, ALS, and VCP disease). It suggests they all share a common problem: The "Sticky Sticker" system is broken.

• The Good News: Because we now know that ZDHHC17 is the machine applying these stickers, scientists might be able to design drugs to fix the machine.
• The Goal: If we can restore the correct amount of "stickiness" to these proteins, we might be able to stop them from getting lost, prevent them from clogging up the cell, and slow down or stop the progression of these devastating diseases.

Summary in One Sentence

This research reveals that a specific enzyme, ZDHHC17, acts as a master organizer that uses "fatty stickers" to keep brain proteins in the right place; when this system fails or goes haywire, it causes proteins to get lost and kill brain cells in Huntington's, ALS, and related diseases, offering a new target for future cures.

Technical Summary

1. Problem Statement

Protein mislocalization is a critical early driver of neurodegeneration, often preceding protein aggregation. While S-acylation (palmitoylation)—the reversible addition of fatty acids to cysteine residues—is known to regulate protein localization and hydrophobicity, the specific mechanisms linking S-acylation defects to multiple distinct neurodegenerative diseases remain poorly defined.

• Context: Previous work established that S-acylation is disrupted in Huntington Disease (HD) and affects the autophagy receptor SQSTM1 (p62).
• Gap: It is unclear if S-acylation defects represent a shared mechanism across other major neurodegenerative diseases, specifically Amyotrophic Lateral Sclerosis (ALS) and Valosin-containing protein-associated Multisystem Proteinopathy (VCP-MSP). Furthermore, the specific S-acyltransferase (ZDHHC enzyme) responsible for modifying key ALS-associated proteins (VCP, TDP-43, FUS, C9orf72) and the functional consequences of these modifications were unknown.

2. Methodology

The study employed a multi-model approach combining biochemical assays, cell biology, and in vivo genetic models:

• Biochemical Assays:
  • Acyl-Biotin Exchange (ABE): Used to detect and quantify S-acylation levels of target proteins (SQSTM1, VCP, TDP-43, FUS, C9orf72) in mouse brain and muscle tissues.
  • Click Chemistry: Utilized alkyne-palmitate (15-HDYA) labeling followed by immunoprecipitation to confirm direct S-acylation of specific proteins.
  • Co-Immunoprecipitation (Co-IP): To identify physical interactions between ZDHHC enzymes and substrate proteins.
• Cell Culture Models:
  • HeLa and HEK293T Cells: Used for overexpression studies of ZDHHC17, ZDHHC9, and disease-associated mutants (e.g., R155H-VCP).
  • Patient-Derived Cells: Lymphoblastoid cells from patients with VCP mutations (R155H) and unaffected family members were analyzed.
  • Toxicity Assays: Trypan Blue exclusion for cell viability; Western blotting for ER stress markers (CHOP).
  • Microscopy: Confocal microscopy to assess protein localization (nuclear vs. cytoplasmic) and paraptotic cell death phenotypes (vacuolization).
• Animal Models:
  • Mouse Models:
    • HD: YAC128 transgenic mice (15-month-old).
    • VCP-MSP: R155H-VCP Knock-In (KI) mice.
    • ALS: TDP-43 M337V transgenic mice.
  • Drosophila Models:
    • Ubiquitous Knockdown: da-Gal4 driving dHip14 (fly ortholog of ZDHHC17) RNAi.
    • Tissue-Specific Knockdown: Motor neuron-specific (OK6-Gal4), pan-neuronal (elav-Gal4), and muscle-specific (mef2-Gal4) knockdowns.
    • Behavioral Assays: Negative geotaxis (climbing) assays to assess motor function over time.

3. Key Contributions

• Discovery of Novel S-Acylation Targets: The study identifies VCP, TDP-43, FUS, and C9orf72 as S-acylated proteins, expanding the known "palmitoylome" of neurodegenerative disease proteins.
• Identification of ZDHHC17 as a Central Node: The paper establishes ZDHHC17 as a critical regulator that interacts with and modifies multiple disease-associated proteins (VCP, TDP-43), linking disparate diseases through a common enzymatic mechanism.
• Mechanistic Insight into Mislocalization: The study elucidates distinct mechanisms by which ZDHHC enzymes drive nuclear depletion:
  • ZDHHC9: S-acylates TDP-43, leading to its cytoplasmic mislocalization.
  • ZDHHC17: Interacts with TDP-43 (S-acylation independent) and S-acylates VCP (S-acylation dependent), both leading to nuclear depletion.
• Link to ER Stress and Paraptosis: Demonstrates that the interaction between ZDHHC17 and VCP induces ER stress (via CHOP upregulation) and paraptotic cell death, characterized by cytoplasmic vacuolization.

4. Key Results

A. S-Acylation Patterns in Disease Models

• Huntington Disease (YAC128 Mice):
  • SQSTM1: S-acylation decreased by ~50% in 15-month-old mice (consistent with human patient data).
  • VCP: S-acylation significantly reduced (~50% decrease).
  • FUS: S-acylation significantly increased, with a sex-specific effect (higher in males).
  • TDP-43 & C9orf72: Detected as S-acylated, but no significant genotype or sex effects observed in this model.
• VCP-MSP (R155H-VCP KI Mice):
  • VCP, TDP-43, SQSTM1, and FUS were confirmed as S-acylated in brain and quadriceps.
  • No significant genotype-dependent changes in S-acylation levels were found in this specific aged model, though the proteins are confirmed as substrates.
• ALS (TDP-43 M337V Mice):
  • TDP-43: S-acylation was significantly increased in the quadriceps of transgenic mice compared to controls, while total TDP-43 protein levels were reduced in muscle but increased in the cortex.

B. ZDHHC17 Interactions and Toxicity

• VCP Modification: ZDHHC17 overexpression significantly increases VCP S-acylation.
• Nuclear Depletion: Co-expression of ZDHHC17 and VCP (WT or R155H mutant) causes significant nuclear depletion of VCP. This effect is exacerbated in paraptotic cells.
• Disease Mutant Specificity: The R155H-VCP mutant shows increased S-acylation compared to WT-VCP in HEK293T cells, Drosophila, and patient-derived lymphoblasts. R155H-VCP also shows increased colocalization with ZDHHC17.
• Cell Death Mechanism: Co-expression of ZDHHC17 and VCP leads to ~25% reduced cell viability, increased CHOP (ER stress marker), and paraptotic vacuoles.

C. In Vivo Functional Consequences (Drosophila)

• Developmental Lethality: Ubiquitous or pan-neuronal knockdown of dHip14 (ZDHHC17) results in pharate adult lethality (flies fail to emerge from pupal cases) or severe developmental defects (limb/wing abnormalities).
• Motor Neuron Specificity: Motor neuron-specific knockdown (OK6-Gal4) allows survival but results in progressive motor deficits (climbing failure) that worsen over 21 days, mimicking ALS-like phenotypes. Muscle-specific knockdown had no significant effect.

5. Significance

• Unified Mechanism: The study proposes that disrupted S-acylation mediated by ZDHHC17 is a convergent mechanism across HD, VCP-MSP, and ALS. It suggests that while the primary genetic mutations differ (HTT, VCP, TDP-43), the downstream failure of protein localization and proteostasis shares a common enzymatic regulator.
• Therapeutic Target: ZDHHC17 is positioned as a critical therapeutic target. Restoring its activity or modulating the S-acylation status of its substrates (like VCP and TDP-43) could potentially rescue protein mislocalization and proteostasis defects.
• Sex Differences: The observation of sex-specific differences in FUS S-acylation in HD models highlights the importance of considering biological sex in neurodegeneration research and therapeutic development.
• Pathological Insight: The link between ZDHHC17-mediated VCP S-acylation and ER stress/paraptosis provides a new cellular mechanism for the toxicity observed in VCP-associated diseases and potentially ALS.

In conclusion, this paper redefines ZDHHC17 as a central hub in neurodegeneration, connecting fatty acylation biology to the mislocalization of key proteins across multiple disease spectrums, offering a novel pathway for future therapeutic intervention.